Changchun High-New's Subsidiary GenSci144 Receives Clinical Trial Approval on May 26

GateNews
According to a company announcement on May 26, Changchun High-New's subsidiary Changchun Jinsai Pharmaceutical received approval from China's National Medical Products Administration for a clinical trial of GenSci144, an orally administered small-molecule inhibitor targeting the SLC6A19 neutral amino acid transporter. GenSci144 is classified as a Category 1 innovative chemical drug and is intended for the treatment of phenylketonuria (PKU).
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments